ADVERTISEMENT
Dr. Lal Pathlabs Q2 Results Review - Inline; Volume Growth Still Lackluster: Yes Securities
The brokerage retains 'Sell' rating on the stock based on unchanged 40x as reckon there is unlikely to be a revenue surprise in the near term that precludes meaningful upgrades.
24 Oct 2024, 09:51 AM IST 
Test tubes with blood samples. Cseh Ioan - Grafvision (Image Source: Envato)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
I’m already a Subscriber Sign In
To continue reading this storySubscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Lite
Experience
Members-Only
Rewards
NDTV Profit
Exclusive Stories
Full Access to
NDTV Profit App
Access to
Stories20,000+
Research Reports
Ad-Lite
Experience
NDTV Profit
Exclusive Stories
Curated
Newsletters
Priority Pass
to Special Events
Members-Only
Rewards
Full Access to
NDTV Profit App
Still Not convinced ? Know More
